InflaRx Strengthens Clinical Leadership with Renal Disease Expert
Event summary
- Gabriela Alperovich, MD, PhD, appointed Senior Vice President & Global Head of Clinical Development at InflaRx, effective October 1, 2026.
- Dr. Alperovich brings over 20 years of experience in clinical development and medical affairs, with a focus on immune-inflammatory renal diseases.
- She previously served as Executive Director, Global Clinical Lead for Cardiovascular and Renal at CSL Vifor.
- InflaRx is advancing izicopan, an orally administered small molecule inhibitor of the C5a receptor, for ANCA-associated vasculitis and other renal indications.
The big picture
InflaRx's appointment of Dr. Alperovich underscores its strategic focus on advancing therapies for immune-inflammatory renal diseases. Her extensive experience in clinical development and regulatory success aligns with InflaRx's goal of bringing innovative treatments to patients with high unmet needs. The move comes as the biopharmaceutical industry increasingly targets the complement system for its role in inflammatory diseases, positioning InflaRx to compete in this growing therapeutic area.
What we're watching
- Clinical Development
- How Dr. Alperovich's expertise will accelerate izicopan's development in ANCA-associated vasculitis and other renal indications.
- Regulatory Strategy
- Whether InflaRx can leverage Dr. Alperovich's track record to streamline regulatory submissions and approvals.
- Pipeline Expansion
- The pace at which InflaRx can expand its pipeline of complement-targeted therapeutics under Dr. Alperovich's leadership.